Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
===============================================================================================================================================================

* Bilal A Siddiqui
* Jinesh S Gheeya
* Rohit Goswamy
* Tharakeswara K Bathala
* Devaki Shilpa Surasi
* Jianjun Gao
* Amishi Shah
* Matthew T Campbell
* Pavlos Msaouel
* Sangeeta Goswami
* Jennifer Wang
* Amado J Zurita
* Eric Jonasch
* Paul G Corn
* Ana M Aparicio
* Arlene O Siefker-Radtke
* Padmanee Sharma
* Sumit K Subudhi
* Nizar Tannir